Biotricity Inc Financials
This page shows Biotricity Inc (BTCY) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Biotricity Inc passes 5 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Biotricity Inc generates $0.28 in operating cash flow (-$2.4M OCF vs -$8.4M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Biotricity Inc earns $-0.8 in operating income for every $1 of interest expense (-$2.4M vs $3.3M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
Biotricity Inc generated $13.8M in revenue in fiscal year 2025. This represents an increase of 14.3% from the prior year.
Biotricity Inc's EBITDA was -$2.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 72.3% from the prior year.
Biotricity Inc reported -$8.4M in net income in fiscal year 2025. This represents an increase of 40.3% from the prior year.
Biotricity Inc earned $-0.56 per diluted share (EPS) in fiscal year 2025. This represents an increase of 66.6% from the prior year.
Cash & Balance Sheet
Biotricity Inc held $365K in cash against $0 in long-term debt as of fiscal year 2025.
Biotricity Inc had 25M shares outstanding in fiscal year 2025. This represents an increase of 167.3% from the prior year.
Margins & Returns
Biotricity Inc's gross margin was 76.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 7.3 percentage points from the prior year.
Biotricity Inc's operating margin was -17.8% in fiscal year 2025, reflecting core business profitability. This is up 55.4 percentage points from the prior year.
Biotricity Inc's net profit margin was -61.1% in fiscal year 2025, showing the share of revenue converted to profit. This is up 55.8 percentage points from the prior year.
Capital Allocation
Biotricity Inc invested $2.2M in research and development in fiscal year 2025. This represents a decrease of 16.2% from the prior year.
BTCY Income Statement
| Metric | Q4'26 | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $11.7M+194.6% | $4.0M+2.6% | $3.9M+0.3% | $3.9M+4.6% | $3.7M+2.3% | $3.6M+10.8% | $3.3M+2.0% | $3.2M |
| Cost of Revenue | $2.2M+198.5% | $736K+4.6% | $704K-7.0% | $757K+4.5% | $724K-15.3% | $855K+5.9% | $808K-3.7% | $839K |
| Gross Profit | $9.5M+193.7% | $3.3M+2.2% | $3.2M+2.1% | $3.1M+4.7% | $3.0M+7.8% | $2.8M+12.4% | $2.5M+4.1% | $2.4M |
| R&D Expenses | $1.9M+208.3% | $624K+3.4% | $603K-13.4% | $696K+21.6% | $573K+3.9% | $551K+6.4% | $518K+0.8% | $514K |
| SG&A Expenses | $6.6M+203.2% | $2.2M-5.1% | $2.3M+7.8% | $2.1M-34.4% | $3.3M+36.9% | $2.4M+5.9% | $2.2M-24.2% | $3.0M |
| Operating Income | $997K+126.0% | $441K+61.0% | $274K-2.9% | $282K+133.0% | -$855K-406.2% | -$169K+45.1% | -$308K+72.5% | -$1.1M |
| Interest Expense | $71K-91.2% | $810K-5.8% | $860K+1.2% | $850K-4.7% | $892K+5.0% | $850K+13.0% | $752K-2.2% | $769K |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | $2.1M+390.1% | -$717K-3.8% | -$691K-2.8% | -$672K+65.3% | -$1.9M-57.5% | -$1.2M+21.3% | -$1.6M+57.7% | -$3.7M |
| EPS (Diluted) | $0.10+335.7% | $-0.04-44.8% | $-0.030.0% | $-0.03 | N/A | $-0.05+26.0% | $-0.07+85.1% | $-0.49 |
BTCY Balance Sheet
| Metric | Q4'26 | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $5.7M0.0% | $5.7M-10.1% | $6.3M+4.7% | $6.0M+7.0% | $5.6M-5.8% | $6.0M+13.1% | $5.3M-2.4% | $5.4M |
| Current Assets | $5.0M0.0% | $5.0M-10.0% | $5.5M+7.6% | $5.1M+10.9% | $4.6M-4.6% | $4.9M+19.6% | $4.1M-0.7% | $4.1M |
| Cash & Equivalents | $256K0.0% | $256K-16.9% | $308K-21.2% | $391K+7.2% | $365K-28.3% | $510K+194.1% | $173K+72.0% | $101K |
| Inventory | $2.0M0.0% | $2.0M-12.5% | $2.3M+26.5% | $1.8M+14.7% | $1.6M-0.9% | $1.6M-13.6% | $1.8M-5.0% | $1.9M |
| Accounts Receivable | $1.6M0.0% | $1.6M-24.8% | $2.1M+12.8% | $1.9M+12.2% | $1.7M+34.2% | $1.2M-17.6% | $1.5M-1.2% | $1.5M |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | -$28.6M-171.5% | $39.9M+0.5% | $39.7M+2.3% | $38.8M+3.1% | $37.7M-0.7% | $37.9M+4.0% | $36.5M+3.6% | $35.2M |
| Current Liabilities | $23.8M0.0% | $23.8M+0.8% | $23.6M+8.3% | $21.8M+5.7% | $20.6M-2.4% | $21.1M-1.6% | $21.5M+4.4% | $20.6M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $34.2M+200.0% | -$34.2M-2.5% | -$33.4M-1.9% | -$32.8M-2.5% | -$32.0M-0.2% | -$31.9M-2.5% | -$31.2M-4.7% | -$29.8M |
| Retained Earnings | $142.1M+200.0% | -$142.1M-0.8% | -$141.0M-0.6% | -$140.2M-0.5% | -$139.4M-1.5% | -$137.4M+1.5% | -$139.4M0.0% | -$139.4M |
BTCY Cash Flow Statement
| Metric | Q4'26 | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $698K+194.3% | -$740K-278.1% | $416K+211.3% | -$373K+6.8% | -$401K-355.0% | -$88K+77.8% | -$397K+73.4% | -$1.5M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Financing Cash Flow | $649K-10.0% | $721K+242.1% | -$508K-216.5% | $436K+164.0% | $165K-61.2% | $425K-9.8% | $471K-45.7% | $868K |
| Dividends Paid | $122K | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
BTCY Financial Ratios
| Metric | Q4'26 | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 81.3%-0.3pp | 81.5%-0.3pp | 81.9%+1.4pp | 80.5%+0.0pp | 80.4%+4.1pp | 76.4%+1.1pp | 75.3%+1.5pp | 73.8% |
| Operating Margin | 8.5%-2.6pp | 11.1%+4.0pp | 7.0%-0.2pp | 7.3%+30.4pp | -23.1%-18.4pp | -4.7%+4.8pp | -9.4%+25.5pp | -34.9% |
| Net Margin | 17.7%+35.7pp | -18.0%-0.2pp | -17.8%-0.4pp | -17.3%+34.9pp | -52.3%-18.3pp | -34.0%+13.9pp | -47.8%+67.6pp | -115.4% |
| Return on Equity | 6.1% | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | 36.6%+49.2pp | -12.6%-1.7pp | -10.9%+0.2pp | -11.1%+23.2pp | -34.3%-13.8pp | -20.5%+9.0pp | -29.5%+38.6pp | -68.2% |
| Current Ratio | 0.210.0 | 0.21-0.0 | 0.230.0 | 0.24+0.0 | 0.220.0 | 0.23+0.0 | 0.190.0 | 0.20 |
| Debt-to-Equity | -0.83+0.3 | -1.17+0.0 | -1.190.0 | -1.180.0 | -1.18+0.0 | -1.19-0.0 | -1.17+0.0 | -1.18 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Note: Shareholder equity is negative (-$32.0M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.22), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
What is Biotricity Inc's annual revenue?
Biotricity Inc (BTCY) reported $13.8M in total revenue for fiscal year 2025. This represents a 14.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Biotricity Inc's revenue growing?
Biotricity Inc (BTCY) revenue grew by 14.3% year-over-year, from $12.1M to $13.8M in fiscal year 2025.
Is Biotricity Inc profitable?
No, Biotricity Inc (BTCY) reported a net income of -$8.4M in fiscal year 2025, with a net profit margin of -61.1%.
What is Biotricity Inc's EBITDA?
Biotricity Inc (BTCY) had EBITDA of -$2.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Biotricity Inc's gross margin?
Biotricity Inc (BTCY) had a gross margin of 76.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Biotricity Inc's operating margin?
Biotricity Inc (BTCY) had an operating margin of -17.8% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Biotricity Inc's net profit margin?
Biotricity Inc (BTCY) had a net profit margin of -61.1% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Biotricity Inc's operating cash flow?
Biotricity Inc (BTCY) generated -$2.4M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Biotricity Inc's total assets?
Biotricity Inc (BTCY) had $5.6M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Biotricity Inc spend on research and development?
Biotricity Inc (BTCY) invested $2.2M in research and development during fiscal year 2025.
What is Biotricity Inc's current ratio?
Biotricity Inc (BTCY) had a current ratio of 0.22 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Biotricity Inc's debt-to-equity ratio?
Biotricity Inc (BTCY) had a debt-to-equity ratio of -1.18 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Biotricity Inc's return on assets (ROA)?
Biotricity Inc (BTCY) had a return on assets of -149.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Biotricity Inc's cash runway?
Based on fiscal year 2025 data, Biotricity Inc (BTCY) had $365K in cash against an annual operating cash burn of $2.4M. This gives an estimated cash runway of approximately 2 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Biotricity Inc's debt-to-equity ratio negative or unusual?
Biotricity Inc (BTCY) has negative shareholder equity of -$32.0M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Biotricity Inc's Piotroski F-Score?
Biotricity Inc (BTCY) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Biotricity Inc's earnings high quality?
Biotricity Inc (BTCY) has an earnings quality ratio of 0.28x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Biotricity Inc cover its interest payments?
Biotricity Inc (BTCY) has an interest coverage ratio of -0.8x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.